Please login to the form below

Not currently logged in
Email:
Password:

Q4 results

This page shows the latest Q4 results news and features for those working in and with pharma, biotech and healthcare.

bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin

bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin

bluebird bio has posted a modest increase in its Q4 revenues and has also provided an update about its clinical hold on its sickle cell disease gene therapy LentiGlobin. ... In its full year 2020 results and operational highlights, bluebird added that

Latest news

  • AZ forecasts growth in 2021 after revenues surge in Q4 AZ forecasts growth in 2021 after revenues surge in Q4

    Shares in AstraZeneca (AZ) were up by over 2% in morning trading after fourth quarter (Q4) sales beat expectations, with strong growth now forecasted for 2021. ... AZ added that this most recent quarter was the first ‘for many years’ in which product

  • Roche’s diagnostic business sales offer a bright spot in Q4 Roche’s diagnostic business sales offer a bright spot in Q4

    Elsewhere in Roche’s Q4 results, the company’s pharmaceuticals division took a hit, slipping 2% in 2020 due to the continuing impact from biosimilars on key products, including its cancer ... However, group sales climbed by 1% overall at constant

  • Sanofi reports a profit in Q4 as Dupixent sales climb Sanofi reports a profit in Q4 as Dupixent sales climb

    Shares in French pharma company Sanofi climbed around 3% in premarket activity after it posted a profit in its 2020 fourth quarter (Q4) results, following a net loss in the same ... For the full year, Dupixent generated sales of 3.5bn, again making gains

  • Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4 Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4

    In Q4 2020, Veklury brought over $1.9bn, while for the full year the antiviral drug produced sales of $2.8bn. ... However, aside from Veklury, there were some other product sale increases among the Q4 results, including growth for Gilead’s cell

  • Pfizer aims for $15bn in 2021 COVID-19 vaccine sales Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

    Current estimate is based on already agreed contracts. Pfizer has forecast major sales expectations for its BioNTech-partnered COVID-19 vaccine, BNT162b2, in its fourth quarter results – aiming for approximately $15bn ... For Pfizer’s total vaccine

More from news
Approximately 17 fully matching, plus 28 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...